Sanofi and Lilly boosted by Novo's shock Tresiba FDA knockback
This article was originally published in Scrip
Sanofi and Lilly have been dealt an unexpectedly positive hand by the surprise decision of the US FDA not to approve Novo Nordisk's novel ultra long-acting once-daily basal insulin product Tresiba (insulin degludec) or the combination treatment Ryzodeg (insulin degludec plus insulin aspart). It now looks like Tresiba's approval in the US may have been set back by three or more years.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.